Explore

Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability

PepGen Reports Positive Progress in FREEDOM2-DM1 Trial with Financial Stability
Trendline Trendline
Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results

Immunome Submits NDA for Varegacestat and Reports Financial Results
Trendline Trendline
Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials

Immunome Advances Oncology Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials

Immunome Advances Cancer Therapy Pipeline with New Drug Application and Clinical Trials
Trendline Trendline
FDA Places Partial Clinical Hold on PepGen's FREEDOM2 Study Amid Safety Concerns

FDA Places Partial Clinical Hold on PepGen's FREEDOM2 Study Amid Safety Concerns

FDA Places Partial Clinical Hold on PepGen's FREEDOM2 Study Amid Safety Concerns
Trendline Trendline
Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients

Partner Therapeutics Gains FDA Approval for Bizengri, Offering New Hope for Cholangiocarcinoma Patients
Trendline Trendline
IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy

IMMEDIATE Therapeutics Expands Leadership to Advance IMT-358 for Ischemic Therapy
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers

Zai Lab Secures FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Cancers
Trendline Trendline
Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas

Zai Lab Gains FDA Fast Track for Zocilurtatug Pelitecan in Treating Aggressive Neuroendocrine Carcinomas
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy with AI Enhancement